← Back to Search

EMPATHY Pilot for Leukemia

N/A
Waitlist Available
Led By David Cella, PhD
Research Sponsored by Northwestern University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

Study Summary

This trial may improve healthcare for those with CML by providing data on the benefits of monitoring patient-reported adverse events and by informing the development of a large international trial testing whether this method could improve clinical response to TKI therapy.

Eligible Conditions
  • Leukemia
  • Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Medication Adherence
Number of Participants Adherent To Their Medication
Secondary outcome measures
Cytogenetic Response
Fatigue
Health-Related Quality of Life

Trial Design

1Treatment groups
Experimental Treatment
Group I: Chronic myeloid leukemia (CML) patientsExperimental Treatment1 Intervention
CML patients undergoing first-line tyrosine kinase inhibitor (TKI) therapy

Find a Location

Who is running the clinical trial?

Fondazione GIMEMA - Franco Mandelli OnlusUNKNOWN
Northwestern UniversityLead Sponsor
1,585 Previous Clinical Trials
917,706 Total Patients Enrolled
27 Trials studying Leukemia
351 Patients Enrolled for Leukemia
National Cancer Institute (NCI)NIH
13,654 Previous Clinical Trials
40,932,367 Total Patients Enrolled
1,511 Trials studying Leukemia
379,588 Patients Enrolled for Leukemia

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
New England Journal of MedicineJournal
Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
Druker, Brian J., Charles L. Sawyers, Hagop Kantarjian, Debra J. Resta, Sofia Fernandes Reese, John M. Ford, Renaud Capdeville, and Moshe Talpaz. 2001. “Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome”. New England Journal of Medicine. Massachusetts Medical Society. doi:10.1056/nejm200104053441402.
BloodJournal
Poor Adherence Is the Main Reason for Loss of Ccyr and Imatinib Failure for Chronic Myeloid Leukemia Patients on Long-term Therapy
Ibrahim, Amr R., Lina Eliasson, Jane F. Apperley, Dragana Milojkovic, Marco Bua, Richard Szydlo, Francois-Xavier Mahon, et al.. 2011. “Poor Adherence Is the Main Reason for Loss of Ccyr and Imatinib Failure for Chronic Myeloid Leukemia Patients on Long-term Therapy”. Blood. American Society of Hematology. doi:10.1182/blood-2010-10-309807.
HematologyJournal
The Value of Quality of Life Assessment in Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitors
Efficace, Fabio, and Laura Cannella. 2016. “The Value of Quality of Life Assessment in Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitors”. Hematology. American Society of Hematology. doi:10.1182/asheducation-2016.1.170.
BloodJournal
Patient-reported Outcomes in Hematology: Is It Time to Focus More on Them in Clinical Trials and Hematology Practice?
Efficace, Fabio, Gianluca Gaidano, and Francesco Lo-Coco. 2017. “Patient-reported Outcomes in Hematology: Is It Time to Focus More on Them in Clinical Trials and Hematology Practice?”. Blood. American Society of Hematology. doi:10.1182/blood-2017-03-737403.
~17 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top